Triggering of TRAIL-R1 and TRAIL-R2 death receptors by their selective fully human agonistic antibodies induces apoptosis in primary and cultured lymphoma cells

被引：0
|
作者：
Georgakis, G
Li, Y
Humphreys, R
Andreeff, M
O'Brien, S
Younes, M
Carbone, A
Albert, V
Younes, A
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Human Genome Sci, Rockville, MD USA
[3] Baylor Coll Med, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [21] Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative
    Wajant, H
    Moosmayer, D
    Wüest, T
    Bartke, T
    Gerlach, E
    Schönherr, U
    Peters, N
    Scheurich, P
    Pfizenmaier, K
    ONCOGENE, 2001, 20 (30) : 4101 - 4106
  • [22] TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
    MacFarlane, M
    Kohlhaas, SL
    Sutcliffe, MJ
    Dyer, MJS
    Cohen, GM
    CANCER RESEARCH, 2005, 65 (24) : 11265 - 11270
  • [23] Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway
    Hao, Zhichao
    Han, Xiaojian
    Sun, Xin
    Shen, Meiying
    Huang, Jingjing
    Li, Yaying
    Ozawa, Tatsuhiko
    Pang, Da
    Jin, Shoude
    Kishi, Hiroyuki
    Muraguchi, Atsushi
    Jin, Aishun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 475 (02) : 238 - 244
  • [24] N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
    Florent Dufour
    Thibault Rattier
    Sarah Shirley
    Gaelle Picarda
    Andrei Alexandru Constantinescu
    Aymeric Morlé
    Al Batoul Zakaria
    Guillaume Marcion
    Sebastien Causse
    Eva Szegezdi
    Dirk Michael Zajonc
    Renaud Seigneuric
    Gilles Guichard
    Tijani Gharbi
    Fabien Picaud
    Guillaume Herlem
    Carmen Garrido
    Pascal Schneider
    Chris Alan Benedict
    Olivier Micheau
    Cell Death & Differentiation, 2017, 24 : 500 - 510
  • [25] N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
    Dufour, Florent
    Rattier, Thibault
    Shirley, Sarah
    Picarda, Gaelle
    Constantinescu, Andrei Alexandru
    Morle, Aymeric
    Zakaria, Al Batoul
    Marcion, Guillaume
    Causse, Sebastien
    Szegezdi, Eva
    Zajonc, Dirk Michael
    Seigneuric, Renaud
    Guichard, Gilles
    Gharbi, Tijani
    Picaud, Fabien
    Herlem, Guillaume
    Garrido, Carmen
    Schneider, Pascal
    Benedict, Chris Alan
    Micheau, Olivier
    CELL DEATH AND DIFFERENTIATION, 2017, 24 (03): : 500 - 510
  • [26] Selective agnostic monoclonal antibodies to the TRAIL receptors R1 and R2 induce cell death and potentiate the effect of chemotherapy and bortezomib in primary and cultured lymphoma cells.
    Georgakis, GV
    Li, Y
    Robin, H
    Andreeff, M
    Susan, O
    Albert, V
    Younes, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 581S - 581S
  • [27] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy
    Carrell, Jeffrey
    Humphreys, Robin
    CANCER RESEARCH, 2009, 69
  • [28] Bortezomib-mediated up-regulation of TRAIL-R1 and TRAIL-R2 (November, pg 6541, 2007)
    Koschny, Ronald
    Holland, Heidrun
    Sykora, Jaromir
    Haas, Tobias L.
    Sprick, Martin R.
    Ganten, Tom M.
    Krupp, Wolfgang
    Bauer, Manfred
    Ahnert, Peter
    Meixensberger, Juergen
    Walczak, Henning
    CLINICAL CANCER RESEARCH, 2007, 13 (23) : 7224 - 7224
  • [29] INVOLVEMENT OF ENDOCYTOSIS IN TRAIL-R1/DR4 AND TRAIL-R2/DR5 TRAFFICKING AND SIGNALING
    Sourkova, V
    Andera, L.
    ADVANCES IN TNF FAMILY RESEARCH, 2011, 691 : 815 - 816
  • [30] Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
    Luster, Troy A.
    Carrel, Jeffrey A.
    McCormick, Kathy
    Sun, David
    Humphreys, Robin
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) : 292 - 302
12345